News & Updates
Filter by Specialty:
ICON8B OS data support a new SoC for epithelial ovarian cancer
In the final overall survival (OS) analysis of the phase III ICON8B trial, first-line treatment with bevacizumab in combination with a chemotherapeutic regimen comprising carboplatin Q3W and dose-dense paclitaxel QW improved survival in women with high-risk stage III-IV epithelial ovarian cancer.
ICON8B OS data support a new SoC for epithelial ovarian cancer
29 Oct 2025
Obesity linked to COVID-19 severity in children during pre-Omicron wave
A recent study has found that individuals with obesity had more severe COVID-19 during the ancestral and pre-Omicron waves, but not during the Omicron wave.
Obesity linked to COVID-19 severity in children during pre-Omicron wave
28 Oct 2025
Nivolumab bests ipilimumab in head-to-head melanoma trial
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Young-onset diabetes: Novel insights on management
At EmW 2025, Professor Andrea Luk from the Department of Medicine & Therapeutics, the Chinese University of Hong Kong, shared insights and recommendations on management of young-onset diabetes (YoD).
Young-onset diabetes: Novel insights on management
28 Oct 2025
HK data: LAI antipsychotics superior to oral antipsychotics in older patients with schizophrenia
Long-acting injectable (LAI) antipsychotics are associated with lower risks of disease relapse and mortality than oral antipsychotics in older patients with schizophrenia, a population-based study in Hong Kong has shown.